Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 16/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | QPCTL | Q9NXS2 | 3/20 | 0.48 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396669 | 0.88 | ALDH1A1 (0.45) | QPCTKDM4EALDH1A1HPGD | |
| SCHEMBL8634290 | 0.77 | QPCT (0.68) | QPCTKDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL1706004 | 0.74 | QPCT (0.64) | QPCTKDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL32691830 | 0.73 | KDM4E (0.50) | KDM4EALDH1A1HPGDBRD4 | |
| SCHEMBL31337313 | 0.73 | TSHR (0.46) | KDM4ENPC1ALDH1A1RAB9AHPGD | |
| SCHEMBL3492185 | 0.72 | DYRK1A (0.53) | KDM4EALDH1A1HPGD | |
| SCHEMBL29458961 | 0.72 | QPCT (0.54) | QPCTKDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL17694561 | 0.71 | NOTUM (0.78) | KDM4EALDH1A1TP53HPGDMAPT | |
| SCHEMBL2474515 | 0.71 | QPCT (0.60) | QPCTKDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL11783195 | 0.70 | QPCT (0.59) | QPCTKDM4ENPC1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542549-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-05-11 | — | — | EP | disclosed |
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | disclosed |
| EP-2542549-A2 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2013-01-09 | — | — | EP | disclosed |
| US-20110224259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
| WO-2011107530-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224259-A1 | NOVEL INHIBITORS | QPCT, GLUL, GLS | QPCT 1/4885KDM4E 494/4885NPC1 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.